ライフサイエンスコーパス: ED50

1 ED50 (the dose producing half-maximal effect) for insuli

2 ED50 also increased in response to glibenclamide in a do

3 ED50 values for Cyto-012 and wt BoNT/A were respectively

4 ED50 values for responses to alphabeta-MeATP were: brady

5 ED50 values were also influenced by asthma control and s

6 ED50, the plasma concentration of adenosine needed to pr

7 ED50s for weight loss and the increase in clamp GIR were

8 bitor (Ki = 2 nM) and antiviral agent (HIV-1 ED50 = 14 nM).

9 HL-60 [ED50, 4 x 10(-9) mol/L] and Kasumi-1 [ED50, 5 x 10(-10) mol/L]).

10 genous H2O2 dilated (%max dilation; 97+/-1%, ED50; 3.0+/-0.7x10(-5) mol/L) and hyperpolarized HCA.

11 (1S,3R)-ACPD ((-)-9 ED50 = 19 mg/kg, (-)-10 ED50 = 14 mg/kg), indicating that these molecules effect

12 e highest protection was demonstrated by 11 (ED50 MES = 88.4 mg/kg, ED50 scPTZ = 59.9 mg/kg, ED50 6 H

13 Tetrazole 19 (ED50 0.18 muM) and oxadiazole-5-thione 25 (ED50 0.36 muM

14 d-Pro2-endomorphin-2 (ED50=0.05 microg) was more potent than endomorphin-2 (ED

15 microg) was more potent than endomorphin-2 (ED50=30 microg) in significantly increasing tail-flick l

16 (ED50 0.18 muM) and oxadiazole-5-thione 25 (ED50 0.36 muM) were 12- and 6-fold more potent, respecti

17 TD50/ED50), 4.46), and 3-benzyl compound 4c (ED50, 41 mg/kg; PI, 7.05) is the most effective anticonv

18 n GLP-1 in db/db mice (effective doses, 50% [ED50s] of 0.059 microg/kg +/-0.15 log and 329 microg/kg+

19 rentiated leukemia cell lines (RA-res HL-60 [ED50, 4 x 10(-9) mol/L] and Kasumi-1 [ED50, 5 x 10(-10)

20 ll as the corresponding hecogenin analog 64 (ED50 = 0.07 mg/kg).

21 lective LTB4 receptor antagonist CP-105,696 (ED50= 8.6 mg/kg orally).

22 botic activity, the most active compound 6b (ED50 = 28.36 mumol/kg po in mice) showed improved inhibi

23 old and suppressed LXRalpha activity by 80% (ED50 approximately 25-50 microm) in HEK293-E (early pass

24 I/group II mGluR agonist (1S,3R)-ACPD ((-)-9 ED50 = 19 mg/kg, (-)-10 ED50 = 14 mg/kg), indicating tha

25 the stimulatory effect of PGE2 by up to 90% (ED50 approximately 0.1 nM).

26 ating cGMP production from cloned rat NPR-A (ED50 = 1.8 nM) and was reduced in NPR-C binding by appro

27 c AMP in HEK-293 cells expressing rat A3ARs (ED50 = 12+/-5 microM); (e) stimulate RBL-2H3 rat mast-li

28 xhibits broad-spectrum analgesic activities (ED50 < or = 4 mg/kg, per os) that are reversible with an

29 e exhibited potent antinociceptive activity (ED50 = 1.1 micrograms/mouse), while N-allyl[D-Pro10]Dyn

30 gue exhibited weak antinociceptive activity (ED50 = 26 micrograms/mouse in the phenylquinone abdomina

31 11) exhibited weak antinociceptive activity (ED50 = 27 micrograms/mouse).

32 1 was shown to have potent topical activity (ED50 = 0.6% in acetone/olive oil) in a stringent swine m

33 food intake model upon oral administration (ED50 at 6 h = 18 mg/kg).

34 7 x 10(-3) microg/mL compared to adriamycin, ED50 = 1.0 x 10(-2) microg/mL).

35 P activated carotid chemoreceptor afferents (ED50 23 +/- 9 nmol), an action that was unaffected by PP

36 gG1) antibody that binds with high affinity (ED50 = 0.15 nmol/L) to RON and effectively blocks intera

37 ERCA-ATPase but displayed a higher-affinity (ED50 < 10 mM) activation by K+, similar to that of the N

38 (ED50 approximately 20 mM) and low affinity (ED50 approximately 70 mM) or by Na+ in a one-step fashio

39 -zona binding with low or moderate affinity (ED50 = 42 microM and 5.3 microM, respectively).

40 e (BG) is a potent inactivator of human AGT (ED50 of 0.1 microM) that is currently undergoing clinica

41 6) having a Ki of 10 nM against MMP-3 and an ED50 of 11 mg/kg po in the mouse pleural cavity assay.

42 maximum increase of 8.1 +/- 2.4 mm Hg and an ED50 of 73 +/- 2.9 micrograms.

43 Cap activated inward current at an ED50 of 728 nM, exhibiting cooperativity (Hill coefficie

44 e model of S. aureus infection exhibiting an ED50 value of 8.4 mg/kg.

45 ed by the tail flick latency test, giving an ED50 of 2.5 mg/kg.

46 y MNNG even in the presence of BG and had an ED50 for the inactivation by BG of 620 microM.

47 -19-nor-cholecalciferol (Ro 25-9716)] had an ED50 of 4 x 10(-11) mol/L; in contrast, the 1,25D3 produ

48 n cellobioside (5, pamaqueside) which has an ED50 of 2 mg/kg.

49 QX 14g has an ED50 value of 1.2 mg/kg iv in the mouse MES assay.

50 rmal escape assay, MABE was found to have an ED50 of 0.027 microg in the rat when administered intrat

51 ient enough to have hypoglycemic potency (an ED50 of 65 micromol/kg, 28 mg/kg/day, for glucose loweri

52 ) mol/L; in contrast, the 1,25D3 produced an ED50 of 10(-9) mol/L with the HL-60 target cells.

53 duced pulmonary hypertension in rats with an ED50 = 0.3 microg/kg/h.

54 1 is a potent P2X7 antagonist with an ED50 = 2.3 mg/kg in rats, high oral bioavailability and

55 agonist 3,5-dihydroxyphenylglycine, with an ED50 = 31 mg/kg (i.p., 60 min preinjection).

56 del, 4 blocked leukotriene formation with an ED50 = 7 mg/kg when administered orally.

57 after DPAT injection) is bell-shaped with an ED50 approximately 1 mg/kg on the ascending limb of the

58 -induced licking in marmoset monkeys with an ED50 estimated at 0.9 mg/kg without producing evidence o

59 141716A evoked thermal hyperalgesia with an ED50 of 0.0012 fmol.

60 derivative of 11-ketotigogenin (51) with an ED50 of 0.025 mg/kg in the hamster assay, as well as the

61 found to exhibit remarkable efficacy with an ED50 of 0.04 mg/kg/day for the reduction of liver choles

62 zed nicotine-induced antinociception with an ED50 of 0.07 microg/kg in the tail-flick assay.

63 ation into skin or into an air pouch with an ED50 of 0.2 mg/kg.

64 diabetic rhesus monkeys by up to 37% with an ED50 of 0.25 microg/kg +/-0.09 log.

65 easing concentrations of glucosamine with an ED50 of 1.95 mM.

66 rses desensitization of AC activity, with an ED50 of 10 microM but does not modulate basal, hCG-stimu

67 n a SCID mouse model of Pf infection with an ED50 of 100 and ED90 of between 100 and 150 mg kg(-1), r

68 SJSA-1 osteosarcoma xenograft model with an ED50 of 11 mg/kg.

69 rates in the presence of bicarbonate with an ED50 of 27 mM for ROS-GC1 and 39 mM for ROS-GC2.

70 ncentration-dependent manner by Mg2+ with an ED50 of 32+/-16 microM.

71 s the most potent inhibitor of edema with an ED50 of 4.7 mpk.

72 SJSA-1 osteosarcoma xenograft model with an ED50 of 41 mg/kg.

73 sentation in a dose-dependent manner with an ED50 of 5 mg/kg.

74 + with Ba2+, but was reduced by Ni2+ with an ED50 of 6+/-1 microM.

75 ation of capillary endothelial cells with an ED50 of 8.5 nM for the D-Ile-15 substitution, 10 nM for

76 nicotine-stimulated dopamine release with an ED50 of 8.6 microM.

77 ntagonist adenylyl-imidodiphosphate, with an ED50 of approximately 0.1 nM.

78 to rat cerebellar membranes ex vivo with an ED50 of approximately 1.3 mg/kg and an oral bioavailabil

79 est in HT29 human colon cancer cells with an ED50 of approximately 115 nm.

80 rat whole body fatty acid oxidation with an ED50 of approximately 30 mg/kg.

81 l extracellular calcium requirements with an ED50 of nearly 100 microM, the magnitude of PS appearanc

82 B67) inhibited tumor growth in vitro with an ED50 ranging between 2 and 40 ng/ml, at least 10-fold mo

83 rom lethal infection of A. baumannii with an ED50 value of <2.0 mg/kg.

84 ctivity against SK-BR-3 (ER-, HER2+) with an ED50 value of 0.10 microg/mL.

85 mM) or by Na+ in a one-step fashion with an ED50 value of approximately 50 mM.

86 ventromedial placements displayed analgesic ED50s on the tail-flick (morphine: 1.4 microgram, M6G: 0

87 cus coeruleus placements displayed analgesic ED50s on the tail-flick (morphine: 1.7 microgram, M6G: 0

88 ueductal gray placements displayed analgesic ED50s on the tail-flick (morphine: 2.1 microgram, M6G: 0

89 In rats, Bavail, appKD, and ED50 were 3.9 +/- 0.4 pmol/mL, 2.2 +/- 0.4 nM, and 12.0

90 ere reduced to a set of binary responses and ED50s were estimated using Probit analysis.

91 (IC50 >100 microM) and weak anticonvulsant (ED50 >10 mg/kg iv).

92 ced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 mug/kg/min, respectively.

93 oth the elevated plus maze model of anxiety (ED50 = 0.5 mg/kg) and in the ACPD-induced limbic seizure

94 in a dose-responsive manner with an apparent ED50 of 100-300 nM.

95 c in BCME cells but exhibited an approximate ED50 of 1.8 to 3.7 nM in BALB/c3T3 fibroblasts.

96 ed antigen induced airway obstruction assay (ED50 2.0 mg/kg, po) and demonstrated a significant reduc

97 fully substituted for LSD in the DD assays (ED50 = 33.5 mumol/kg), neither 8 nor 9 substituted for L

98 (14 and 19) exhibit efficacy against MRSA at ED50 values of approximately 1 and approximately 5 mg/kg

99 alcium release, because of a decrease in BDK ED50 values.

100 T is strongly inhibited by O6-benzylguanine (ED50, 0.2 microM), and this drug is presently undergoing

101 that mutant P140K is highly resistant to BG (ED50 of >1200 microM).

102 of this mutant was strongly resistant to BG (ED50 of 180 microM).

103 and dermatan sulfate inhibited gB2 binding (ED50 = 1 to 5 microg/ml), indicating that gB2 interacts

104 ceptor assays (ID50) and in vitro bioassays (ED50), it became evident that signal transduction correl

105 7) M) and other PPARgamma ligands (BRL49653: ED50, 8 x 10(-8) M; 15-deoxy-delta12,14-prostaglandin J2

106 Dopamine (DA) at ca. ED50 (16 microg) or saline was stereotaxically microinje

107 a in a dose-related manner with a calculated ED50 of 2.1 mg/kg, i.p.

108 ed (ED50=1.20-1.60 microgram) and castrated (ED50=1.08-1.09 micrograms) male rats displayed significa

109 F alpha) are strong mitogens for 1H91 cells (ED50 of 9.02 + 1.74 ng/ml and 15.98 +/- 2.34 ng/ml, resp

110 oduction and up to 3-fold increases in cGMP (ED50 = 30 microM for RASM, 50 microM for aorta).

111 glandin J2: ED50, 2 x 10(-6) M; ciglitizone: ED50, not reached; indomethacin: ED50, not reached) show

112 te RBL-2H3 rat mast-like cell degranulation (ED50 = 2.3+/-0.9 microM); and (f) cause mast cell-depend

113 10 to 20 minutes, were lipid dose-dependent (ED50=4.5+/-1.4 mg), and were quantitatively reproducible

114 A-317491 dose-dependently (ED50 = 30 micromolkg s.c.) reduced complete Freund's adj

115 de reversed the antiseizure activity of DOC (ED50, 7.2 mg/kg); partial antagonism was also obtained w

116 romal cell cultures from both normal donors (ED50 = 0.5 nM) and MM patients.

117 morphine half-maximal antinociceptive dose (ED50) values.

118 design in vivo with a median effective dose (ED50) of 1 mg/kg following a single dose.

119 excess of 90%, with a median effective dose (ED50) of 1.5nM, whereas the maximum gene silencing effic

120 ncentrations of heparin (50% effective dose [ED50] = 0.08 microg/ml).

121 ture rats following both sc and oral dosing (ED50 of 0.006 and 0.25 mg/kg, respectively).

122 ent inhibitors of carrageenan-induced edema (ED50 = 9-30 mpk) and hyperalgesia (ED50 = 11-40 mpk).

123 normalized SBP (151+/-2 mm Hg; P<.05), EDR (ED50, 7.33+/-.08; P<.05), left ventricular hypertrophy (

124 P (225+/-6 mm Hg) but modestly improved EDR (ED50: 6.07+/-.37; P<.05 versus hypertensive DS) as well

125 litazone showed an antiproliferative effect (ED50, 3 x 10(-7) M) and other PPARgamma ligands (BRL4965

126 10(-9) M) and in the absence of endothelium (ED50 of 10(-9) M).

127 th the peptide and analogue were equipotent (ED50=0.5 microg) in significantly increasing jump thresh

128 The estimated ED50 was 30 micrograms, and the maximum depression of no

129 odel, compound 14 promoted sodium excretion (ED50=0.01 mg/kg).

130 e most potent bioactivity in HSCs expansion (ED50 = 5.21 nM).

131 Fluorescein angiography thresholds (FAVL-ED50) were also determined using a probit analysis of th

132 FAVL-ED50s were much higher than MVL-ED50s, showing that FA w

133 l challenge model (capsaicin-induced flinch, ED50 = 0.33 mg/kg p.o.) and was antihyperalgesic in a mo

134 QX-314 had the following ED50 values (mg/kg) for neuromas, DRG and DH neurons, re

135 the adjuvant induced arthritis model (e.g., ED50 = 0.02 mpk for 22 and 34).

136 n such as the rat formalin paw model (GP3269 ED50= 6.4 mg/kg).

137 (ca. 8 times greater than 1 in mice at 4 h, ED50 = 6.3 mg/kg; ca. 15 times greater than 1 in rats at

138 ca. 15 times greater than 1 in rats at 8 h, ED50 = 1.0 mg/kg) with a long duration of action (>24 h

139 2b), and 7-methyl-5-(N-oxyaza)-QX (12c) have ED50 values of 0.82, 0.87, and 0.97 mg/kg i.v., respecti

140 ither by K+ in a two-step fashion with high (ED50 approximately 20 mM) and low affinity (ED50 approxi

141 er or longer spacers have >/=500-fold higher ED50s in LPS-treated mice, the exceptional potency of MM

142 ed edema (ED50 = 9-30 mpk) and hyperalgesia (ED50 = 11-40 mpk).

143 y in females such that no sex differences in ED50 were observed.

144 O synthesis were additive, with increases in ED50 as high as 15-fold.

145 k test, resulting in significantly increased ED50 values for both agonists in this strain.

146 iglitizone: ED50, not reached; indomethacin: ED50, not reached) showed similar effects.

147 ronic pain models, A-317491 was ineffective (ED50 >100 micromolkg s.c.) in reducing nociception in an

148 f analogs producing a 50% clonal inhibition (ED50) ranged between 1 x 10(-9) to 4 x 10(-11) mol/L whe

149 de (1, tiqueside) which is a weak inhibitor (ED50 = 60 mg/kg) as measured in an acute hamster cholest

150 ost potent member of the series (intrathecal ED50 approximately 9 fmol per mouse), whereas in untreat

151 tracellular amastigotes: responsive isolates ED50=2.4+/-2.6, ED90=6.4+/-7.8 microgram SAG/mL; unrespo

152 -7.8 microgram SAG/mL; unresponsive isolates ED50=7.4+/-3.7 microgram SAG/mL, ED90=29.1+/-11.1 SAG/mL

153 ol per mouse), whereas in untreated mice its ED50 was more than three orders of magnitude higher.

154 -8) M; 15-deoxy-delta12,14-prostaglandin J2: ED50, 2 x 10(-6) M; ciglitizone: ED50, not reached; indo

155 0 MES = 88.4 mg/kg, ED50 scPTZ = 59.9 mg/kg, ED50 6 Hz = 21.0 mg/kg).

156 vity in these models (ED50 MES = 79.5 mg/kg, ED50 6 Hz = 22.4 mg/kg).

157 s demonstrated by 11 (ED50 MES = 88.4 mg/kg, ED50 scPTZ = 59.9 mg/kg, ED50 6 Hz = 21.0 mg/kg).

158 .4+/-0.4% (1 mg/kg) to 14.8+/-2.6% (5 mg/kg; ED50=1.9 mg/kg).

159 The safety margin (intramuscular LD50/ED50 ratio) for Cyto-012 was found to be improved 2-fold

160 ble, and displaceable with unlabeled leptin (ED50: 0.73 +/- 0.09 nM, mean +/- SEM, n = 3).

161 gB2 binding to heparin only at high levels (ED50 = 65 microg/ml).

162 in elevating FAS, ACC, and GPDH mRNA levels (ED50 approximately 0.5 mm).

163 In protocol 1, 50% success levels, ED50, were measured after 15 seconds of fibrillation for

164 Lidocaine ED50 values (expressed as mg/kg, with 95% confidence lim

165 lonal growth of NB4 cells, an APL cell line (ED50, approximately 5 x 10(-11) M).

166 against MCF-7 (breast carcinoma) cell lines (ED50 = 3.7 x 10(-3) microg/mL compared to adriamycin, ED

167 as compared to their wild-type littermates (ED50, 167 mg/kg).

168 axation responses and sensitivity (i.e.,-log ED50) to isoproterenol (P < 0.005).

169 In protocol 1, QSBW had a lower ED50, 16.0+/-4.9 J, than TEBW, 20.3+/-4.4 J, or CDSMW, 2

170 Asthmatic patients had higher Emax and lower ED50 values than healthy volunteers.

171 thmatic patients, patients with CC had lower ED50 values (14.7 mumol/L [relative SE, 28%], P = .008)

172 evel of long chain fatty acids and a lowered ED50 for glucose-induced insulin secretion.

173 The LY2795050 ED50 at MOR was 119 mug/kg based on a 1-site model for (

174 and GPDH (633%) in a dose-dependent manner (ED50 8-16 mm).

175 mic accumulation in a dose-dependent manner (ED50 = 0.3 nm).

176 er and therefore combined for analysis (mean ED50, 38.6 mumol/L [relative SE, 28%]; mean Emax, 4.5 co

177 : 1, 1 : 1, and 1 : 3) relative to the mean ED50 for each drug alone.

178 tractive anticonvulsant profile (PTZ and MES ED50 values of 2.8 and 9.2 mg/kg, respectively).

179 nvulsant activity, with eudysmic ratios (MES ED50 in mice at 4 h, po) of 1:106 = 1.5 and 2:107 = 3.5.

180 E12 showed potent silencing effects in mice (ED50 approximately 0.002 mg/kg), rats (ED50 < 0.01 mg/kg

181 oinflammatory cytokine IL-2 ex vivo in mice (ED50 approximately 5 mg/kg) and in reducing TNF levels i

182 oxin, and amygdala-kindled seizures in mice (ED50 values, 84-97 mg/kg).

183 tivity was undiminished in female PRKO mice (ED50, 172 mg/kg) as compared to their wild-type litterma

184 and audiogenic stimulation in Fring's mice (ED50 = 206.4 mg/kg).

185 fter rectal mustard oil application to mice (ED50=2.35 mg/kg).

186 nd was 5,480-fold more potent in ob/ob mice (ED50s of 0.136 microg/kg+/-0.10 log and 744 microg/kg+/-

187 hemokines, was able to mediate MK migration (ED50 = 125 pmol/liter).

188 ved oral efficacy in the rat diuresis model (ED50=0.01 mg/kg) as well as high oral bioavailability in

189 nd in vivo activity in a rat diuresis model (ED50=0.3 mg/kg po).

190 stradiol-induced murine uterine edema model (ED50 = 3 mg/kg) superior to Sutent (ED50 = 9 mg/kg) and

191 activity only in the MMP-3 injection model (ED50 = 6 mg/kg iv).

192 oral efficacy in the rat formalin paw model (ED50 of 2.5 mg/kg).

193 nd in the ACPD-induced limbic seizure model (ED50 = 45.6 mg/kg).

194 in pentylenetetrazole-induced seizure model (ED50 PTZ = 123.2 mg/kg).

195 CT-116 colorectal carcinoma xenograft model (ED50 = 10 mg/kg QD).

196 oth the SJSA-1 osteosarcoma xenograft model (ED50 = 2.6 mg/kg QD) and the HCT-116 colorectal carcinom

197 in the SJSA-1 osteosarcoma xenograft model (ED50 = 9.1 mg/kg).

198 est anticonvulsant activity in these models (ED50 MES = 79.5 mg/kg, ED50 6 Hz = 22.4 mg/kg).

199 harmacodynamic effect in cynomolgus monkeys (ED50 0.12 mg/kg) and in DIO mice.

200 Morphine ED50 values obtained at various infusion intervals demon

201 Although morphine ED50 values were significantly increased in both sexes r

202 th potency for normalization of GI motility (ED50 = 0.17 mg/kg).

203 For all pulse widths, the 24-hour MVL-ED50 was lower than the 1-hour MVL-ED50, and they both d

204 -hour MVL-ED50 was lower than the 1-hour MVL-ED50, and they both decreased with decreasing pulse widt

205 Visible lesion thresholds (MVL-ED50) were determined 1 hour and 24 hours after exposure

206 FAVL-ED50s were much higher than MVL-ED50s, showing that FA was not as sensitive in determini

207 r by nifedipine (ED50=159+/-54 nM) and Ni2+ (ED50=65+/-16 microM) but were enhanced when external Ca2

208 oncentration-dependent manner by nifedipine (ED50=159+/-54 nM) and Ni2+ (ED50=65+/-16 microM) but wer

209 tantly, po administration was also observed (ED50 of 0.07 and 2.8 mg/kg, respectively).

210 , such as 23c and 23e, with oral efficacy of ED50 of 8 and 5.1 mg/kg, respectively, in rat spinal ner

211 Both sham-operated (ED50=1.20-1.60 microgram) and castrated (ED50=1.08-1.09

212 35 has an oral ED50 of 0.1 mg/kg in the rat FCA model of inflammatory p

213 Point mutations such as P140A (ED50, 5 microM) render AGT resistant to O6-benzylguanine

214 nce to BG but to a lesser extent than P140K (ED50s of 190 and 7 microM, respectively).

215 female rats tested during the estrous phase (ED50=>50 micrograms) were significantly less sensitive t

216 = 286 nm), partial reduction of PKCepsilon (ED50 > 10 microm), and no effect on PKCalpha.

217 nt of intact fibrinogen (purified or plasma; ED50% approximately 5 pmol Aalpha chain equivalents/mL),

218 roduced a dose-dependent suppression of PMR [ED50 of 0.44 microg (0.33-0.58)], as well as tonic and a

219 hyl)-2-(trifluoromethyl)-9H- purine (80) (po ED50 of 2 mg/kg), which was obtained through an iterativ

220 patocyte cultures with comparable potencies (ED50 = 5.0 and 18 nM, respectively), and significantly i

221 SO conjugates exhibited excellent potencies (ED50 0.5-2 mg/kg) for reducing the targeted mRNAs and pr

222 overall in vivo profile in terms of potency (ED50 = 0.04 mumol/kg) and safety.

223 A-317491 was most potent (ED50 = 10-15 micromolkg s.c.) in attenuating both therma

224 by kallistatin was observed in the presence (ED50 of 3.4 x 10(-9) M) and in the absence of endotheliu

225 the [Ca2+] required for the latter process (ED50 = approximately 200 microM) appears to be reached o

226 11) M greater than 50% clonal proliferation (ED50) of the MCF-7 and SK-BR-3 breast cancer cells, incr

227 lso inhibited in their clonal proliferation (ED50, 5 x 10(-11) mol/L) and their expression of CD11b w

228 found by use of extracellular promastigotes (ED50=48+/-22 vs. 52+/-29 microgram/mL).

229 ly induced loss from the cytosol of RasGRP3 (ED50 = 286 nm), partial reduction of PKCepsilon (ED50 >

230 osynthesis derived from OSC inhibition (rat, ED50 = 1.3 +/- 0.7 mg/kg, n = 5; marmoset, 15 mg/kg dose

231 to morphine than ovariectomized female rats (ED50=1.98-2.51 micrograms).

232 mice (ED50 approximately 0.002 mg/kg), rats (ED50 < 0.01 mg/kg), and nonhuman primates (over 95% sile

233 y alphabeta-MeATP in 62 % of units recorded (ED50 22 +/- 5 nmol) and this was blocked by PPADS (17 mi

234 s, it was possible to determine the relative ED50 values for the entire array of molecules simultaneo

235 excellent correlation between these relative ED50 values and a series of relative Kd values determine

236 d higher affinities for sperm, respectively (ED50 = 500 and 430 nM).

237 ive morphine anti-nociceptive dose-response (ED50) was tested and hyperactive behaviors such as jumpi

238 psaicin dose inducing half-maximal response (ED50).

239 psaicin dose inducing half-maximal response (ED50).

240 a potent axon-promoting factor for rat RGCs (ED50 approximately 10 microm); this response was cAMP-de

241 ependent relaxations (EDRs) in aortic rings (ED50, 5.44+/-.18 versus 7.51+/-.10; P<.05) and mesenteri

242 when administered by both iv and po routes (ED50 = 0.06 and 6 mg/kg, respectively).

243 nM in a dose-dependent manner within 30 sec (ED50 of approximately 5 x 10(-9) M).

244 against pentylenetetrazole-induced seizures (ED50, 37 mg/kg; PI (TD50/ED50), 4.46), and 3-benzyl comp

245 a model (ED50 = 3 mg/kg) superior to Sutent (ED50 = 9 mg/kg) and showed potent antitumor efficacy in

246 cer exhibited profound antinociception (i.t. ED50 = 0.0146 pmol/mouse) that was 2000x greater than mo

247 e-induced seizures (ED50, 37 mg/kg; PI (TD50/ED50), 4.46), and 3-benzyl compound 4c (ED50, 41 mg/kg;

248 The protective indices (PI = TD50/ED50) (where TD50 represents a neurotoxic dose impairing

249 t activities and protective indices (PI=TD50/ED50) that compared favorably with clinical antiseizure

250 The ED50 at KOR estimated from the 1-site model was 15.6 mug

251 The ED50 dose was further increased in rats receiving both m

252 The ED50 for apnoea was significantly greater than that for

253 The ED50 for delivered energy for the dual current pathway R

254 The ED50 for translocation of PKCalpha/alpha was 26 nM, in m

255 The ED50 of ISO (dose of ISO resulting in 50% of the maximal

256 The ED50 of the NSP4 effect on peak [Ca2+]i mobilization was

257 The ED50 value was 65% lower in female patients (P = .0001)

258 zer Pc 4 [HOSiPcOSi(CH3)2(CH2)3N(CH3)2], the ED50 for ceramide generation (46 nM) was similar to the

259 nor MK-801 produced analgesia or altered the ED50 value of morphine.

260 125I-PLA2-I binding to its receptor and the ED50 values for PLA2-I-induced ECM-invasion.

261 ofectamine RNAiMAX was less than 60% and the ED50 was 25nM.

262 lectroshock-induced seizure (MES) assay: the ED50 was 2.8 mg/kg iv, whereas the ED50 for GYKI 52466 w

263 GLUT4 mRNA also declined, but the ED50 was approximately 5 nM.

264 owever, when the two drugs are combined, the ED50 effect is achieved with only 0.34 mg/kg SRL per day

265 with paclitaxel or Adriamycin decreased the ED50 for inhibition of colony formation or for cell deat

266 To estimate the ED50 value (dose of a compound [or drug] that gives 50%

267 sical dependence nor place preference in the ED50 dose range.

268 tail showed a significant right shift in the ED50 for opioid-mediated analgesia, while mice treated w

269 R/MOR heteromer after the right shift in the ED50 had occurred, or blocking signal transduction from

270 d delta1 selectivity due to increases in the ED50 ratios of [D-Ser2,Leu5]enkephalin-Thr6 and morphine

271 doses produced a progressive increase in the ED50 that peaked at 3 wk in mice, consistent with prior

272 r up to 6 wk with no further increase in the ED50.

273 addition of both CdtA and CdtC increased the ED50 for CdtB >7000-fold.

274 el of adjuvant-induced arthritis in rat, the ED50 of 5 (0.9 mg/kg) was superior to that of both 1a an

275 he stabilized DOR/MOR heteromer, shifted the ED50 for analgesia back to the left.

276 nic phase of the biphasic formalin test, the ED50 was 129+/-32 mg/kg.

277 acetic acid abdominal constriction test, the ED50 was 56+/-9 mg/kg, a concentration similar to those

278 13 J, which was significantly lower than the ED50 of the standard single current pathway RAap to DCS

279 se of 1 mg/kg (over 100-fold higher than the ED50).

280 Thus, the ED50 ratio for MOR:KOR was 7.6.

281 a/alpha was 26 nM, in marked contrast to the ED50 of 0.9 nM in the case of the PKCalpha/epsilon chime

282 ssay: the ED50 was 2.8 mg/kg iv, whereas the ED50 for GYKI 52466 was 4.6 mg/kg iv.

283 This ED50 was within the range reported by the manufacturer,

284 mma2 in OCs, resulting in diminished TRAP5b (ED50 = 17 nM) and bone resorption activity.

285 m preantral follicles, R-spondin2 treatment (ED50: 3 ng/ml) synergized with Wnt3a to stimulate Wnt si

286 Following 2 weeks of each treatment, ED50 dose was significantly increased in rats receiving

287 PV1-mediated physiological response in vivo (ED50 = 1.9 mg/kg, p.o. in the capsaicin-induced flinch m

288 t cerebral cortex synaptosomes) and in vivo (ED50 per os in mice on brain tele-methylhistamine levels

289 xity against A549, A431, 1A9, and HCT-8 with ED50 values of 1.0, 1.2, 0.9, and 1.3 mug/mL, respective

290 -116 and HT-29 human colon cancer cells with ED50 values of 134.4 and 217.0 mug/mL after 48 h of trea

291 ) demonstrated strong cytotoxic effects with ED50 values in the nanomolar or subnanomolar range in al

292 in infected whole cells (erythrocytes) with ED50 values down to 55 nM.

293 receptor occupancy at low doses in rat with ED50 values of 0.06 and 0.07 mg/kg, respectively.

294 nduced obese mice, and obese Zuker rats with ED50 values of 1.9 mg/kg, 6.8 mg/kg, and 0.73 mg/kg, res

295 howed the best activity and selectivity with ED50 values of 0.45 and 0.18 microg/mL against MCF-7 and

296 t activity in the rat MES seizure assay with ED50s < or = 2.0 mg/kg, ip, and showed relatively mild s

297 muscle, and cardiac muscle malonyl-CoA with ED50s of 55, 6, 15, and 8 mg/kg.

298 hesis in rats, CD1 mice, and ob/ob mice with ED50s of 13, 11, and 4 mg/kg, and stimulated rat whole b

299 mbining analgesic potency in mouse writhing (ED50 = 0.1 mg/kg) along with potency for normalization o

300 MGO, morphine, and DPDPE were found to yield ED50 values of 0.14, 2.4, and 54 microg, respectively, i